Literature DB >> 22051874

Heart failure is associated with reduced patency after endovascular intervention for symptomatic peripheral arterial disease.

Andrew J Meltzer1, Gautam Shrikhande, Katherine A Gallagher, Francesco A Aiello, Sikandar Kahn, Peter Connolly, James F McKinsey.   

Abstract

OBJECTIVE: Congestive heart failure (CHF) is a highly prevalent comorbidity among patients with symptomatic peripheral arterial disease. The effect of CHF on the procedural success of endovascular treatment, however, remains unknown. Theoretically, poor inflow secondary to systolic dysfunction and peripheral vascular alterations may predispose endovascular interventions to failure.
METHODS: A retrospective review of a prospectively maintained database was performed to identify CHF patients undergoing endovascular peripheral arterial intervention from 2004 to 2009. Demographics, comorbidities, procedural details, and outcomes were analyzed. Patients underwent duplex ultrasound imaging and clinical follow-up at scheduled intervals. Kaplan-Meier and Cox proportional hazards models were used to evaluate risk factors for loss of primary patency, secondary patency, and limb salvage.
RESULTS: Of 1220 patients undergoing intervention, 271 (22%) with documented congestive heart failure (CHF) underwent an intervention for claudication (22.5%) or critical limb ischemia (77.5%). Primary patency at 1 year was 51.9% ± 2.5% among those with CHF vs 64.6% ± 1.3% in those without CHF (P < .001); this disparity continued throughout follow-up (P < .001). Patients with CHF also had reduced secondary patency throughout follow-up. Multivariate analysis showed CHF was an independent predictor of reduced primary patency (hazard ratio [HR], 1.2; 95% confidence interval [CI] 1.0-1.4; P = .038) and secondary patency (HR, 1.5; 95% CI, 1.2-1.8; P < .001). In the setting of CHF, 1-year patency was 56.6% ± 4.1% if the ejection fraction (EF) was >40% (n = 147) vs 43.2% ± 3.5% if the EF was <40% (n = 124; P < .001). Secondary patency was also significantly reduced in patients with EF <40% throughout follow-up compared with patients without CHF (n = 949) as well as those with CHF and EF >40% (P < .001). CHF with EF <40% was an independent predictor of reduced primary patency (HR, 1.4; 95% CI, 1.2-1.8; P < .01) and secondary patency (HR, 1.8; 95% CI, 1.3-2.3; P < .001). Limb salvage was also worse in patients with EF <40% (P = .038).
CONCLUSIONS: CHF is associated with reduced patency after peripheral endovascular intervention and is an independent risk factor for patency loss. Specifically, CHF and reduced EF (<40%) is a strong independent risk factor for patency loss.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22051874     DOI: 10.1016/j.jvs.2011.08.016

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  One year clinical outcomes of Rutherford 6 chronic limb threatening ischemia patients undergoing lower limb endovascular revascularisation from Singapore.

Authors:  Rui En Lee; Ankur Patel; Shereen Xue Yun Soon; Sze Ling Chan; Charyl Jia Qi Yap; Sivanathan Chandramohan; Luke Hsien Ts'ung Tay; Tze Tec Chong; Tjun Yip Tang
Journal:  CVIR Endovasc       Date:  2022-07-06

2.  Sex-Related Differences in the Outcomes of Endovascular Interventions for Chronic Limb-Threatening Ischemia: Results from the LIBERTY 360 Study.

Authors:  Stefanos Giannopoulos; Nicolas W Shammas; Ian Cawich; Cezar S Staniloae; George L Adams; Ehrin J Armstrong
Journal:  Vasc Health Risk Manag       Date:  2020-07-08

3.  Association between heart failure and perioperative outcomes in patients undergoing non-cardiac surgery.

Authors:  Nathaniel R Smilowitz; Darcy Banco; Stuart D Katz; Joshua A Beckman; Jeffery S Berger
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2021-01-25

4.  Synergistic effects of elevated homocysteine level and abnormal blood lipids on the onset of stroke.

Authors:  Lu Hao; Liming Chen; Xiaoyong Sai; Zhefeng Liu; Guang Yang; Rongzeng Yan; Lili Wang; Caiyun Fu; Xuan Xu; Zhenzhen Cheng; Qiang Wu; Shuzhang Li
Journal:  Neural Regen Res       Date:  2013-11-05       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.